<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542696</url>
  </required_header>
  <id_info>
    <org_study_id>CTH-301</org_study_id>
    <secondary_id>2016-000637-43</secondary_id>
    <nct_id>NCT02542696</nct_id>
  </id_info>
  <brief_title>An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of &quot;OFF&quot; Episodes in Patients With Parkinson's Disease</brief_title>
  <official_title>An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (&quot;OFF&quot; Episodes)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 24-week, prospective, multi-center, open-label, Phase 3 study in L-Dopa responsive PD
      patients with motor fluctuations (&quot;OFF&quot; episodes), designed to evaluate the long-term safety,
      tolerability and efficacy of APL-130277.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2015</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety and tolerability data collected, including 12-lead ECGs, orthostatic hypotension, oropharyngeal and dopaminergic AEs, and other pertinent safety parameters.</measure>
    <time_frame>Throughout the entire study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>APL-130277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL-130277</intervention_name>
    <description>Used to treat up to 5 &quot;OFF&quot; episodes per day</description>
    <arm_group_label>APL-130277</arm_group_label>
    <other_name>Apomorphine Hydrochloride, Sublingual Thin Film</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        De Novo Patients:

        Inclusion Criteria

          1. Male or female ≥ 18 years of age.

          2. Clinical diagnosis of Idiopathic PD, consistent with UK Brain Bank Criteria (excluding
             the &quot;more than one affected relative&quot; criterion) .

          3. Clinically meaningful response to L-Dopa as determined by the Investigator.

          4. Receiving stable doses of L-Dopa/carbidopa (immediate or CR) administered at least 4
             times per day OR Rytary™ administered at least 3 times per day, for at least 4 weeks
             before the initial Screening Visit (SV1). Adjunctive PD medication regimens must be
             maintained at a stable dose for at least 4 weeks prior to the initial Screening Visit
             (SV1) with the exception that MAO-B inhibitors must be maintained at a stable level
             for at least 8 weeks prior to the initial Screening Visit (SV1).

          5. No planned medication change(s) or surgical intervention anticipated during the course
             of study.

          6. Patients must experience at least one well defined &quot;OFF&quot; episode per day with a total
             daily &quot;OFF&quot; time duration of ≥ 2 hours during the waking day, based on patient self
             assessment.

          7. Patient and/or caregiver must be trained in performing home dosing diary assessments
             of the motor state and must be able to recognize &quot;ON&quot; and &quot;OFF&quot; states.

          8. Stage III or less on the modified Hoehn and Yahr scale in the &quot;ON&quot; state.

          9. MMSE score &gt; 25.

         10. If female and of childbearing potential, must agree to be sexually abstinent or use
             one of the following highly effective methods of birth control:

               -  Hormonal contraceptives (eg, combined oral contraceptives, patch, vaginal ring,
                  injectables, and implants);

               -  Intrauterine contraceptive system; Protocol CTH-301, Version 4.00 APL-130277
                  Confidential and Proprietary 57 30 May 2017

               -  Surgical sterilization or partner sterile (must have documented proof); AND

             One of the following effective methods of birth control:

               -  Male/female condom;

               -  Cervical cap with spermicide;

               -  Diaphragm with spermicide;

               -  Contraceptive sponge.

         11. Male subjects must be either surgically sterile, agree to be sexually inactive or use
             a double-barrier method of birth control (eg, condom and diaphragm with spermicide,
             condom with cervical cap and spermicide) from first study drug administration until 90
             days after final drug administration.

         12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study-related procedures.

         13. Able to understand the consent form, and to provide written informed consent.

        Exclusion Criteria

          1. Atypical or secondary parkinsonism.

          2. Previous treatment with any of the following: a neurosurgical procedure for
             PD;continuous s.c. apomorphine infusion; Duodopa/Duopa; or APL-130277.

          3. Treatment with any form of s.c. apomorphine within 7 days prior to the second
             Screening Visit (SV2). Patients that stopped s.c. apomorphine for any reason other
             than systemic safety concerns or lack of efficacy may be considered.

          4. Contraindications to APOKYN®, or hypersensitivity to apomorphine hydrochloride or any
             of the ingredients of APOKYN® (notably sodium metabisulfite).

          5. Female who is pregnant or lactating.

          6. Participation in a clinical trial within 30 days prior to the initial Screening Visit
             (SV1).

          7. Receipt of any investigational (ie, unapproved) medication within 30 days prior to the
             initial Screening Visit (SV1).

          8. Currently taking selective 5HT3 antagonists (ie, ondansetron, granisetron, dolasetron,
             palonosetron, alosetron), dopamine antagonists (excluding quetiapine or clozapine) or
             dopamine depleting agents.

          9. Drug or alcohol dependency in the past 12 months.

         10. Subject has a history of malignancy within 5 years prior to the Screening visit,
             except for adequately treated basal cell or squamous cell skin cancer or in situ
             cervical cancer. Pituitary tumors of any duration are excluded.

         11. Clinically significant medical, surgical, or laboratory abnormality in the opinion of
             the Investigator.

         12. Major psychiatric disorder including, but not limited to, dementia, bipolar disorder,
             psychosis, or any disorder that, in the opinion of the Investigator, requires ongoing
             treatment that would make study participation unsafe or make treatment compliance
             difficult.

         13. History of clinically significant hallucinations during the past 6 months.

         14. History of clinically significant impulse control disorder(s).

         15. Dementia that precludes providing informed consent or would interfere with
             participation in the study.

         16. Current suicidal ideation within one year prior to the second Screening Visit (SV2) as
             evidenced by answering &quot;yes&quot; to Questions 4 or 5 on the suicidal ideation portion of
             the C-SSRS or attempted suicide within the last 5 years.

         17. Donation of blood or plasma in the 30 days prior to first dosing.

         18. Presence of canker or mouth sores in the 30 days prior to the initial Screening Visit
             (SV1), or other clinically significant oral pathology in the opinion of the
             Investigator. The Investigator should follow-up with an appropriate specialist on any
             finding, if indicated, before enrolling a patient into the study.

        Patients Rolling Over from CTH-201, CTH-203, CTH-300, or CTH-302.(Rollover Patients):

        Inclusion Criteria

          1. Completion of any of the following studies: CTH-201, CTH-203, CTH-300, or CTH-302;
             and, in the opinion of the Investigator, would benefit from continued treatment with
             APL-130277.

          2. No major increases in concomitant PD medications since completion of any of the
             following studies: CTH-201, CTH-203, CTH-300, or CTH-302. Any change in PD medications
             since the previous study should be discussed with the Medical Monitor to determine
             patient eligibility in the current study.

          3. If female and of childbearing potential, must agree to be sexually abstinent or use
             one of the following highly effective methods of birth control:

               -  Hormonal contraceptives (eg, combined oral contraceptives, patch, vaginal ring,
                  injectables, and implants);

               -  Intrauterine contraceptive system;

               -  Surgical sterilization or partner sterile (must have documented proof); AND

             One of the following effective methods of birth control:

               -  Male/female condom;

               -  Cervical cap with spermicide;

               -  Diaphragm with spermicide;

               -  Contraceptive sponge.

          4. Male subjects must be either surgically sterile, agree to be sexually inactive or use
             a double-barrier method of birth control (eg, condom and diaphragm with spermicide,
             condom with cervical cap and spermicide) from first study drug administration until 90
             days after final drug administration.

          5. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study-related procedures.

          6. Able to understand the consent form, and to provide written informed consent.

        Exclusion Criteria

          1. Female who is pregnant or lactating.

          2. Presence of any major psychiatric disorder including, but not limited to, dementia,
             bipolar disorder, psychosis (including clinically significant hallucinations during
             the past 6 months) or any disorder that, in the opinion of the Investigator, requires
             ongoing treatment that would make study participation unsafe or make treatment
             compliance difficult.

          3. Presence of any clinically significant medical (including CNS or CV events), surgical,
             or laboratory abnormality that would make study participation unsafe or make treatment
             compliance difficult. Clinical significance to be determined by the Investigator.

          4. Receipt of any investigational (ie, unapproved) medication or participation in any
             clinical trial since completing a previous study using APL-130277.

          5. Development of canker or mouth sores since completing a previous clinical study using
             APL-130277. For other clinically significant oral pathology, the Investigator should
             follow-up with an appropriate specialist on any finding, if indicated, before
             enrolling such a patient into the study. Clinical significance to be determined by the
             Investigator.

          6. Current suicidal ideation as evidenced by answering &quot;yes&quot; to Question 4 or 5 on the
             suicidal ideation portion of the C-SSRS at the Screening Visit (SV1).

        Completer Patients-patients who have previously completed CTH-301 study

        Inclusion Criteria:

          1. Completion of the CTH-301 study, and in the opinion of the Investigator, would benefit
             from continued treatment with APL-130277.

          2. If female and of childbearing potential, must agree to be sexually abstinent or use
             one of the following highly effective methods of birth control:

               -  Hormonal contraceptives (eg, combined oral contraceptives, patch, vaginal ring,
                  injectables, and implants);

               -  Intrauterine contraceptive system;

               -  Surgical sterilization or partner sterile (must have documented proof); AND

             One of the following effective methods of birth control:

               -  Male/female condom;

               -  Cervical cap with spermicide;

               -  Diaphragm with spermicide;

               -  Contraceptive sponge.

          3. Male subjects must be either surgically sterile, agree to be sexually inactive or use
             a double-barrier method of birth control (eg, condom and diaphragm with spermicide,
             condom with cervical cap and spermicide) from first study drug administration until 90
             days after final drug administration.

          4. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study-related procedures.

          5. Able to understand the consent form, and to provide written informed consent.

        Exclusion Criteria:

          1. Female who is pregnant or lactating.

          2. Presence of any major psychiatric disorder including, but not limited to, dementia,
             bipolar disorder, psychosis (including clinically significant hallucinations during
             the past 6 months) or any disorder that, in the opinion of the Investigator, requires
             ongoing treatment that would make study participation unsafe or make treatment
             compliance difficult.

          3. Presence of any clinically significant medical (including CNS or CV events), surgical,
             or laboratory abnormality that would make study participation unsafe or make treatment
             compliance difficult. Clinical significance to be determined by the Investigator.

          4. Receipt of any investigational (ie, unapproved) medication or participation in any
             clinical trial since completing the CTH-301 study.

          5. Development of canker or mouth sores since completing the CTH-301 study. For other
             clinically significant oral pathology, the Investigator should follow-up with an
             appropriate specialist on any finding, if indicated, before enrolling such a patient
             into the study. Clinical significance to be determined by the Investigator.

          6. Current suicidal ideation as evidenced by answering &quot;yes&quot; to Question 4 or 5 on the
             suicidal ideation portion of the C-SSRS at the Screening Visit Phase 2 (SVP2).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CNS Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CNS Medical Director</last_name>
    <phone>1-866-503-6351</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Richardson</last_name>
      <phone>205-934-0074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Muhammed Ali Parkinson and Movement Disorder Center/Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Shelton</last_name>
      <phone>602-406-9593</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Movement Disorders Center of Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Ortega</last_name>
      <phone>480-526-5441</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Parkinson's and Movement Disorder Institute</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Briana Bruckler</last_name>
      <phone>714-378-5074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health Gottschalk Medical Plaza</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaclyn Alcazar</last_name>
      <phone>949-824-1114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keck Medical Center at USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Barles</last_name>
      <phone>323-442-5723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research center of southern california</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Steinert, MD</last_name>
      <phone>303-724-4172</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sasha Warren</last_name>
      <phone>202-444-6941</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkinsons Disease and Movement Disorders Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fannie Levinson</last_name>
      <phone>561-392-1818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami, Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Vargas</last_name>
      <phone>305-243-3647</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease Treatment Center of Southwest Florida</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Seymour</last_name>
      <phone>941-743-4987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suncoast Neuroscience Associates Inc.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Lever</last_name>
      <phone>727-202-2623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>USF Parkinson's Disease and Movement Disorder Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh Donharl</last_name>
      <phone>813-396-0763</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Department of Neurology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Louise Weeks</last_name>
      <phone>404-712-6999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>GRU Movement Disorders</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Buff Farrow</last_name>
      <phone>706-721-0619</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Rutkowski</last_name>
      <phone>312-503-1999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Chmura</last_name>
      <phone>312-942-8002</phone>
      <phone_ext>4</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>NorthShore Neurological Institute B043D</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Anderson</last_name>
      <phone>847-503-4322</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central DuPage Hospital - Neurodegenerative Clinic - Movement Disorders Center</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Komal Sharma</last_name>
      <phone>630-933-6844</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Dept. of Neurology</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeri Sieren</last_name>
      <phone>319-356-8744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center-Department of Neurology</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Langhammer</last_name>
      <phone>913-588-6989</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Wagner</last_name>
      <phone>859-323-0028</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Callison</last_name>
      <phone>443-827-0677</phone>
    </contact>
    <contact_backup>
      <last_name>Terra Hill</last_name>
      <phone>443-827-0677</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Stacy</last_name>
      <phone>433-287-7850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan State University - Dept. of Neurology</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doozie Russel</last_name>
      <phone>517-884-2274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Bardram</last_name>
      <phone>248-957-8940</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Neurology</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Churchill</last_name>
      <phone>248-661-6270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Park Nicolet Institute - Stuthers Parkinson's Center</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Berrington</last_name>
      <phone>952-993-5903</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>David L. Kreitzman, MD, PC</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Bendheim Parkinson's and Movement Disorder Center (Mount Sinai Medical Center)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Bratton</last_name>
      <phone>212-241-0279</phone>
    </contact>
    <contact_backup>
      <last_name>Mindy Lopez</last_name>
      <phone>212 241 0279</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Neurological Institute, Movement Disorders</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Servi</last_name>
      <phone>212-305-3938</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University - Movement Disorders Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen White-Tong</last_name>
      <phone>919-668-2905</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates, P.A.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schwartz</last_name>
      <phone>919-719-8826</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Dimos</last_name>
      <phone>336-716-8694</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Espay</last_name>
      <phone>513-558-6517</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Wyant</last_name>
      <phone>216-444-1179</phone>
    </contact>
    <contact_backup>
      <last_name>Chris Firestone</last_name>
      <phone>2164455637</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Daley</last_name>
      <phone>614-688-8672</phone>
    </contact>
    <contact_backup>
      <last_name>Katherine Ambrogi</last_name>
      <phone>614-688-6685</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UT Gardner-McMaster Parkinson's Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Spears</last_name>
      <phone>419-383-6728</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Movement Disorder Clinic of Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Klos</last_name>
      <phone>918-392-4530</phone>
      <phone_ext>5</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jefferson University Hospital Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lealh Shabo</last_name>
      <phone>215-503-3213</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reema Patel</last_name>
      <phone>215-829-7128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shonna Jenkins</last_name>
      <phone>843-792-9115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia Arif</last_name>
      <phone>713-363-8390</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Texas Medical Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanetta Patterson</last_name>
      <phone>903-531-8850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Adult Neurology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>322903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Sullivan</last_name>
      <phone>434-982-6599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sentara Neuroscience Institute</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Richardson</last_name>
      <phone>757-507-0642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evergreen Health</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Fierro</last_name>
      <phone>425-899-3115</phone>
    </contact>
    <contact_backup>
      <last_name>Marsha Merrick</last_name>
      <phone>(425) 899-3115</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Research</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Maassel</last_name>
      <phone>206-320-7121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UHN Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kings College, The Maurice Wohl Neuroscience Institute</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manchester University</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M68HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newcastle University</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <state>Northumberland</state>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Forth Valley Royal Hospital</name>
      <address>
        <city>Larbert</city>
        <state>Stirlingshire</state>
        <zip>FK54WR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fairfield General Hospital</name>
      <address>
        <city>Bury</city>
        <zip>BL9 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare Trust NHS</name>
      <address>
        <city>London</city>
        <zip>W68RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Plymouth University</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apomorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

